EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Gut mycobiome in metabolic diseases: Mechanisms and clinical implication

Xingyu Zhou, Xiang Zhang, Jun Yu

Biomedical Journal · 2024-06 · 47 (3) · 100625

DOI: 10.1016/j.bj.2023.100625 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomedical Journal, 2024-06. Verfasst von Xingyu Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health S…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Mycobiome, Metabolic Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity, type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are three common metabolic diseases with high prevalence worldwide. Emerging evidence suggests that gut dysbiosis may influence the development of metabolic diseases, in which gut fungal microbiome (mycobiome) is actively involved. In this review, we summarize the studies exploring the composition changes of gut mycobiome in metabolic diseases and mechanisms by which fungi affect the development of metabolic diseases. The current mycobiome-based therapies, including probiotic fungi, fungal products, anti-fungal agents and fecal microbiota transplantation (FMT), and their implication in treating metabolic diseases are discussed. We highlight the unique role of gut mycobiome in metabolic diseases, providing perspectives for future research on gut mycobiome in metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeMycobiomeMetabolic DiseasesHumansDysbiosisDiabetes Mellitus, Type 2ProbioticsFecal Microbiota TransplantationNon-alcoholic Fatty Liver DiseaseAnimalsFungi

Stichwörter der Autor:innen

FungiMycobiomeNAFLDObesityType 2 diabetes

Autor:innen und Institutionen

  • Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China. El…

Zitieren

APA

Zhou, X., Zhang, X., & Yu, J. (2024). Gut mycobiome in metabolic diseases: Mechanisms and clinical implication. Biomedical Journal, 47(3), 100625. https://doi.org/10.1016/j.bj.2023.100625

Vancouver

Zhou X, Zhang X, Yu J. Gut mycobiome in metabolic diseases: Mechanisms and clinical implication. Biomedical Journal. 2024;47(3):100625. doi:10.1016/j.bj.2023.100625

BibTeX
@article{Zhou2024,
  author = {Zhou, Xingyu and Zhang, Xiang and Yu, Jun},
  title = {Gut mycobiome in metabolic diseases: Mechanisms and clinical implication},
  journal = {Biomedical Journal},
  year = {2024},
  volume = {47},
  number = {3},
  pages = {100625},
  doi = {10.1016/j.bj.2023.100625}
}
Kostenlos starten →